Malady Kyle 4

What Happened

• Malady Kyle, EVP and Group CEO — VZ Business, was granted 129.025 units of phantom stock on 2026-04-23. The award is reported as a derivative acquisition (transaction code A) at a per‑unit value of $13.47, equal to about $1,738 in economic value. This was an award/grant (not an open‑market purchase or sale).

Key Details

• Transaction date: 2026-04-23; SEC filing date: 2026-04-24 (timely filing).
• Units granted: 129.025 phantom shares; valuation: $13.47/unit; total ≈ $1,738.
• Security type: derivative (phantom stock), cash‑settled — no new common shares issued.
• Shares owned after transaction: not disclosed in the filing.
• Footnotes: F1 — each phantom share is the economic equivalent of a portion of one common share and is settled in cash; payability is governed by the reporting person's elections under the deferred compensation plan. F2 — includes phantom stock acquired through dividend reinvestment.

Context

• Phantom stock is a deferred, cash‑settled award that tracks the value of common shares; it does not transfer actual voting shares or directly change outstanding common stock. Such awards compensate executives but are different from purchases or sales that signal immediate insider buying/selling.